[Oral anticoagulation for atrial fibrillation].

The correct oral anticoagulation for prevention of thromboembolic events in patients with atrial fibrillation and a corresponding risk profile is essential. However, anticoagulation is not carried out according to the guidelines in all patients. The direct oral anticoagulants (DOACs) are a new treatment alternative to vitamin K antagonists. The new guidelines of the European Society of Cardiology (ESC), recent study results and the practice guidelines of the European Heart Rhythm Association (EHRA) can help to use DOACs appropriately, to optimize the prevention of thromboembolic events in patients with atrial fibrillation and to reduce complications.